Loading...
Please wait, while we are loading the content...
Similar Documents
Photodynamic Compounds and Methods for Activating Them Using Ionizing Radiation And/or Other Electromagnetic Radiation for Therapy And/or Diagnostics
| Content Provider | The Lens |
|---|---|
| Abstract | A method for destroying cells and/or microorganisms in an organism includes the following steps: (a) administering to the organism a composition including a photodynamic compound containing at least one transition metal; and (b) irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation includes ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The ionizing radiation is preferably X-rays and/or gamma rays. The non-ionizing radiation is preferably light in the range from 600-950 nm. |
| Related Links | https://www.lens.org/lens/patent/010-478-839-678-34X/frontpage |
| Language | English |
| Publisher Date | 2017-10-26 |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Patent |
| Jurisdiction | United States of America |
| Date Applied | 2017-04-20 |
| Applicant | Theralase Tech Inc Univ Health Network |
| Application No. | 201715492801 |
| Claim | A method for destroying cells and/or microorganisms in an organism, said method comprising: administering to the organism a composition comprising a photodynamic compound containing at least one transition metal; and irradiating the photodynamic compound in the organism with electromagnetic radiation, wherein the electromagnetic radiation comprises ionizing radiation and is effective to activate the photodynamic compound to destroy at least one of the cells and the microorganisms in the organism. The method of claim 1 , wherein the cells are hyperproliferating cells. The method of claim 1 , wherein the microorganisms are at least one member selected from the group consisting of bacteria, viruses and fungi. The method of claim 1 , wherein the organism is a human. The method of claim 1 , wherein the composition is adminstered by topical, oral, buccal, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, intraventricular, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, vaginal, ophthalmic, pulmonary or rectal routes. The method of claim 1 , wherein the composition is pharmaceutically acceptable and further comprises at least one pharmaceutically acceptable carrier, excipient or diluent. The method of claim 1 , wherein the composition further comprises a metal-binding glycoprotein. The method of claim 7 , wherein the metal-binding glycoprotein is transferrin. The method of claim 1 , wherein the irradiating step comprises irradiating the organism with non-ionizing radiation in a range from 600-950 nm and with at least one of X-rays and Gamma rays. The method of claim 1 , wherein the irradiating step comprises irradiating the organism with 0.1 to 100 Gy of X-ray radiation and with non-ionizing radiation in a range from 600-950 nm. The method of claim 10 , wherein the organism is irradiated with the X-ray radiation and the non-ionizing radiation in an order and at a power which are synergistically effective to: (a) inhibit proliferation of hyperproliferating cells in the organism and/or (b) destroy microorganisms in the organism. The method of claim 1 , which is conducted without a molecular conjugate comprising a radioluminescent molecule and a photosensitizer. The method of claim 1 , wherein the photodynamic compound is a metallosupramolecular complex containing at least one transition metal selected from the group consisting of osmium, manganese, molybdenum, rhenium, ruthenium, iron, cobalt, rhodium, iridium, nickel, platinum, and copper. The method of claim 1 , wherein the photodynamic compound has the formula (I): including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: M at each occurrence is independently selected from the group consisting of osmium, ruthenium and rhodium; X is selected from the group consisting of Cl − , PF 6 − , Br − , BF 4 − , ClO 4 − , CF 3 SO 3 − , and SO 4 −2 ; n=0, 1, 2, 3, 4, or 5; q is independently at each occurrence 0, 1, or 2; y is independently at each occurrence 0, 1, or 2; z is independently at each occurrence 1, 2, or 3; Lig 1 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of Lig 2 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of Lig 3 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of R 1 is selected from the group consisting of hydrogen, optionally substituted phenyl, optionally substituted aryl, optionally substituted heteroaryl, 4-pyridyl, 3-pyridyl, 2-thiazole, 2-pyrolyl, 2-furanyl, u is an integer; R 2a , R 2b , R 2c , R 2d , R 2e , R 2f , R 2g , R 2h , R 2i , R 2j , R 2k , and R 2l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 3-7 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , SO 3 H, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , and R 3l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, optionally substituted phenyl, and CO 2 R 8 ; R 4a , R 4b , and R 4c at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 4a and R 4b at each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms; R 5 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 6 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 7 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and R 8 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alky The method of claim 1 , wherein the photodynamic compound has the formula (VI): including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof wherein; M 1 and M 2 at each occurrence is independently selected from the group consisting of osmium, manganese, molybdenum, rhenium, ruthenium, iron, cobalt, rhodium, iridium, nickel, platinum, and copper; A 2 is selected from the group consisting of t is an integer. The method of claim 1 , wherein the photodynamic compound has the formula (VIIa) including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof wherein: A 3 is selected from the group consisting of Lig 1 is a bidentate ligand that at each occurrence is each independently selected from the group consisting of u is an integer; R 2a , R 2b , R 2c , R 2d , R 2e , R 2f , R 2g , R 2h , R 2i , R 2j , R 2k , and R 2l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 3-7 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , SO 3 H, sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , and R 3l at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, optionally substituted phenyl, and CO 2 R 8 ; R 4a , R 4b , and R 4c at each occurrence are each independently selected from the group consisting of hydrogen, C 1-6 optionally substituted alkyl, C 1-6 optionally substituted branched alkyl, C 1-6 optionally substituted cycloalkyl, C 1-6 optionally substituted haloalkyl, C 1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 4a and R 4b at each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms; R 5 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 6 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 7 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl; and R 8 at each occurrence are each independently selected from the group consisting of hydrogen and optionally substituted alkyl p is independently at each occurrence 0, 1, or 2; q is independently at each occurrence 0, 1, or 2; and n is 0, 1, 2, 3, 4, or 5. The method of claim 1 , wherein the photodynamic compound has the formula (II) including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein: M is selected from the group consisting of manganese, molybdenum, rhenium, iron, ruthenium, osmium, cobalt, rhodium, iridium, nickel, platinum, and copper; X is selected from the group consisting of Cl − , PF 6 − , Br − , BF 4 − , ClO 4 − , CF 3 SO 3 − , and SO 4 −2 ; n=0, 1, 2, 3, 4, or 5; y=1, 2, or 3; z=0, 1, or 2; Lig at each occurrence is independently selected from the group consisting of R 1 is selected from the group consisting of u is an integer; R 2a , R 2b , R 2c , R 2d , R 2e , and R 2f at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted branched alkyl, C3-7 optionally substituted cycloalkyl, C1-6 optionally substituted haloalkyl, C1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 3a , R 3b , R 3c , R 3d , R 3e , R 3f , R 3g , R 3h , R 3i , R 3j , R 3k , R 3l , and R 3m at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted branched alkyl, C1-6 optionally substituted haloalkyl, C1-6 optionally substituted alkoxy, and CO 2 R 8 ; R 4a , R 4b and R 4c at each occurrence are each independently selected from the group consisting of hydrogen, C1-6 optionally substituted alkyl, C1-6 optionally substituted branched alkyl, C1-6 optionally substituted cycloalkyl, C1-6 optionally substituted haloalkyl, C1-6 optionally substituted alkoxy, CO 2 R 5 , CONR 6 2 , NR 7 2 , sulfate, sulfonate, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, and optionally substituted heterocycle; R 4a and R 4b at each occurrence on a thiophene ring are taken together with the atom to which they are bound to form an optionally substituted ring having from 6 ring atoms containing 2 oxygen atoms; R 5 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 6 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl; R 7 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alkyl; and R 8 at each occurrence is independently selected from the group consisting of hydrogen and optionally substituted alky The method of claim 1 , wherein the photodynamic compound has a structure selected from the group consisting of: |
| CPC Classification | Electrotherapy;Magnetotherapy;Radiation Therapy;Ultrasound Therapy Preparations For Medical; Dental Or Toiletry Purposes Devices For Introducing Media Into; Or Onto; The Body ;Devices For Transducing Body Media Or For Taking Media From The Body ;Devices For Producing Or Ending Sleep Or Stupor |
| Extended Family | 010-478-839-678-34X 119-090-020-506-533 |
| Patent ID | 20170304648 |
| Inventor/Author | Mandel Arkady Fisher Carl Lilge Lothar |
| IPC | A61N5/10 A61K33/24 A61K33/243 A61K41/00 A61M5/00 A61M31/00 A61M35/00 A61M37/00 |
| Status | Active |
| Owner | Theralase Technologies Inc University Health Network |
| Simple Family | 010-478-839-678-34X 119-090-020-506-533 |
| CPC (with Group) | A61N5/10 A61K31/4745 A61K33/24 A61K33/243 A61K41/0057 A61N5/062 A61N2005/1098 A61K31/28 A61K31/282 A61K31/295 A61K31/30 A61M5/00 |
| Issuing Authority | United States Patent and Trademark Office (USPTO) |
| Kind | Patent Application Publication |
